Bleeding Events and Oral Anticoagulant Treatment in Non-Valvular Atrial Fibrillation

Bristol-Myers Squibb (BMS)

Status: Withdrawn

Conditions: Non-valvular Atrial Fibrillation

Study type: Observational

Funder types: Industry

Identifiers

NCT03002740

CV185-491

Details and patient eligibility

About

In a population of patients with non-valvular atrial fibrillation (NVAF), and treated with oral anticoagulants (OAC) in routine clinical practice in England, this study will describe patients treated with each OAC, and to estimate and compare event rates of treatment discontinuation, bleeding, and healthcare resource utilisation (HCRU) across OAC treatments.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Have a prescription for apixaban, rivaroxaban, dabigatran, or VKA during the study period
2. Are ≥ 18 years of age at index date
3. Have ≥ 12 months of computerised medical data prior to index date (date of OAC initiation)
4. Have a record of AF on or ever prior to index date

Exclusion criteria

1. Have a record for a valvular condition that is considered causal for AF on or ever prior to index date
2. Have a history of the OACs which are prescribed during the study period (ie, history of index OAC, as patients need to be newly prescribed either apixaban, rivaroxaban, dabigatran, or VKA)
3. Have more than 1 OAC exposure which starts on the same date

Trial design

0 participants in 4 patient groups

NVAF patients newly prescribed apixaban

NVAF patients newly prescribed rivaroxaban

NVAF patients newly prescribed dabigatran

NVAF patients newly prescribed VKA